The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.
about
Signaling effectors underlying pathologic growth and remodeling of the heartGood and bad sides of TGFβ-signaling in myocardial infarctionMMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.Cardiovascular risks associated with low dose ionizing particle radiationThe case for inhibiting p38 mitogen-activated protein kinase in heart failureA-kinase anchoring protein Lbc coordinates a p38 activating signaling complex controlling compensatory cardiac hypertrophyp38 MAP kinases in the heartp38 MAPK-dependent small HSP27 and αB-crystallin phosphorylation in regulation of myocardial function following cardioplegic arrestSodium Tanshinone IIA Sulfonate Prevents Radiation-Induced Toxicity in H9c2 CardiomyocytesEffects of antidepressants on IP-10 production in LPS-activated THP-1 human monocytes.Synergy between sphingosine 1-phosphate and lipopolysaccharide signaling promotes an inflammatory, angiogenic and osteogenic response in human aortic valve interstitial cells.Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectivesDesign, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK.AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.Modulation of p38 kinase by DUSP4 is important in regulating cardiovascular function under oxidative stressLow-dose radiation affects cardiac physiology: gene networks and molecular signaling in cardiomyocytes.The p38 MAP kinase pathway modulates the hypoxia response and glutamate receptor trafficking in aging neuronsMuscle RING-finger 2 and 3 maintain striated-muscle structure and functionMitogen-activated protein kinase-activated protein kinases 2 and 3 regulate SERCA2a expression and fiber type composition to modulate skeletal muscle and cardiomyocyte function.Disruption of TAB1/p38α interaction using a cell-permeable peptide limits myocardial ischemia/reperfusion injury.Abrogation of CC chemokine receptor 9 ameliorates ventricular remodeling in mice after myocardial infarction.Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in MiceDo p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and FibrosisTherapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease.Saffron (Crocus sativus) pretreatment confers cardioprotection against ischemia-reperfusion injuries in isolated rabbit heart.Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction.p38γ and δ promote heart hypertrophy by targeting the mTOR-inhibitory protein DEPTOR for degradation.p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts.Diet-induced obesity promotes altered remodeling and exacerbated cardiac hypertrophy following pressure overload.Ephrin-Eph signaling as a potential therapeutic target for the treatment of myocardial infarction.Repression of the Central Splicing Regulator RBFox2 Is Functionally Linked to Pressure Overload-Induced Heart Failure.Impaired mitochondria and intracellular calcium transients in the salivary glands of obese rats.Oxygen- and temperature-dependent expression of survival protein kinases in crucian carp (Carassius carassius) heart and brain.P2X7 receptor regulates sympathoexcitatory response in myocardial infarction rats via NF-κB and MAPK pathways.SDF-1 induces TNF-mediated apoptosis in cardiac myocytes.TAB1-induced auto-activation of p38α mitogen-activated protein kinase is crucially dependent on Threonine 185.Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease.
P2860
Q26825154-CF80C38F-D3AF-47FC-A38F-505CF93CAE74Q26863465-66A4A50B-5310-49FA-A99B-CC53F35E6E4DQ27302407-872BCEFF-52F2-4F7B-B8FA-3B6495A6F288Q27335261-DB7EA6CC-F3A1-46E8-A6A5-375BF0C88813Q28080674-06D85F77-225D-485A-878E-C515C0F9E3F7Q28570967-482355C1-71F0-4052-B879-9816BB4A32DAQ28603117-93100C79-C6ED-4903-A85D-E0D641503C09Q30500231-5B8543ED-2DAA-4CE7-B563-70CBC7AFAC53Q32178695-512B2A2F-7D70-4633-B6B3-43ECF9DA8B63Q34158301-61E80723-98D3-4C62-B29D-2BB8469A11D3Q34282317-8AA1FC4D-04D6-4767-9B89-D2111059CFA0Q34289211-AA382AE7-F0C3-46F1-A18E-D0D0658B2EDCQ35236755-A7093862-5B55-49C8-AE70-E7BBDFB6283AQ36048973-07F9BC56-4AED-4913-875D-A8E70CE347E3Q36386379-4982DA91-5517-46D8-BE39-A67CB736411FQ36422429-626E5AF3-FFEB-48F9-BD73-8105793E13E0Q36642175-A2324998-8644-4FA7-B6C2-19F4C0ECE4E6Q36892025-76F98C4D-C2D9-4E53-AEAC-106CBC54B09FQ36978298-A41A6D6D-91AD-4EF3-9AAF-0649C0FE109EQ37181412-8D6FDF40-B2FB-49B8-9326-F873ED4F00E0Q37227823-BFC4DE20-24D3-4C45-B377-B9BBDA6BB801Q37238755-0B124EF8-C366-4F06-83D9-B7A95DFB537BQ37329529-6F28639C-649F-4120-A361-8D37D787A49AQ37588749-5DA317DA-1EC8-4FE0-BEF1-991CB44EF014Q38185979-0CB9C781-F3C7-4432-A5D4-0D09170C1603Q38323383-BB0E0B13-01B4-46AE-B93F-37D875AF6957Q39506406-F9AFF5D9-0A64-4EDD-A580-6E907713B972Q40435871-0780E04D-B3D6-4BC4-91BC-D80DCBD9CBF8Q41093817-6CE09D72-1D84-4FA6-9D84-A98E130F78A5Q42231382-534166A7-0200-4657-9CAB-EA8DA9E830E5Q42582216-ED4D7DD9-B043-4873-AC9F-E600904D53D1Q42782593-5EDD2CAB-444C-4C24-BCA8-88DBD576A010Q43084824-A432419F-071C-45AB-BB2A-02CE5AEF63E7Q46421196-37D87037-DE06-4B15-ABEB-C8CE468679A5Q46817106-57713450-DC31-43AE-B1E3-FD080CA7D896Q47096478-619B8C12-42C5-45E9-B864-87DDB9323214Q47298475-8C0C1920-0E47-44F8-B96B-5770AA5AA4BBQ47305269-9EC2128E-1819-4D22-BE05-70E02E8C13FFQ47871357-75836909-8B4D-4E5B-BABB-B63387829A75Q48000590-A5F69CBB-0C79-4933-AD25-4580EA23160B
P2860
The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@ast
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@en
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@nl
type
label
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@ast
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@en
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@nl
prefLabel
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@ast
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@en
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@nl
P2860
P1476
The p38 mitogen-activated prot ...... ypertrophy, and heart failure.
@en
P2093
P2860
P304
P356
10.1016/J.YJMCC.2010.10.021
P577
2010-11-06T00:00:00Z